logo
  

Oshkosh Q4 Profit Declines, But Results Beat View; Hikes Dividend - Quick Facts

Oshkosh Corp. (OSK) on Thursday reported fourth-quarter net income of $100.0 million or $1.46 per share, down from $150.0 million or $2.17 per share in the year-ago period.

Adjusted earnings for the quarter were $1.30 per share, compared to $2.17 per share in the prior-year period.

Consolidated net sales in the quarter decreased 18.7 percent to $1.78 billion from $2.20 billion, reflecting a 39 percent decrease in sales in the Access Equipment segment as the COVID-19 pandemic continued to impact demand in this segment.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.09 per share for the quarter on revenues of $1.66 billion. Analysts' estimates typically exclude special items.

Oshkosh said its board of directors declared a quarterly cash dividend of $0.33 per share of common Stock. The dividend, increased by 10 percent from the previous dividend, will be payable on November 30, 2020, to shareholders of record as of November 16, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT